Drug Development

Video spotlights company's drug candidates to treat multiple myeloma, leukemia

Published in Blood Weekly, November 10th, 2005

Callisto Pharmaceuticals, Inc., (KAL, CA4) a developer of new drug treatments in the fight against hematological cancers and related diseases, has released a corporate video that spotlights the company's lead anticancer drug candidates, Atiprimod and Annamycin.

In the video, CEO Gary S. Jacob outlines Callisto's drug development programs and describes some of the key anticipated medical and marketplace advantages of the company's two drug candidates, Atiprimod and Annamycin, which are being developed as treatments for relapsed multiple myeloma and relapsed leukemia, respectively. Patients are referred to as "relapsed" when they fail to respond to standard chemotherapy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2005-11-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry